glp 1 agonist indications for GLP-1/GIP RA Summary Sheet and Beyond! GLP1 medicines now address weight

See the difference for yourself: 83% of commercial insurance plans require prior authorization, step therapy, or both before a patient can access a GLP-1 prescribed for obesity

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)

Country Segmental Analysis 20.4.2

10.1523/JNEUROSCI.0115-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar] MietlickiBaase, E

In people with obesity, particularly in cases of rapid or marked weight reduction, the decline in lean mass may account up to 2530% of the total weight loss, contributing to the so-called sarcopenic obesity [18]

How to act: Use 3 daily checkpoints: hydrate early (morning + midday + mid-afternoon), protein anchor (repeatable breakfast or lunch), and mini-meals (smaller, more frequent eats)